Royalty Pharma IPO
Royalty Pharma is the largest buyer of biopharmaceutical royalties, providing capital to innovators and owning royalties on marketed and development-stage biopharmaceutical products. The company generates revenue from royalty payments on successful drugs across various therapeutic areas. Investors were attracted to its diversified portfolio of pharmaceutical royalties and predictable cash flows.
What We Know
Royalty Pharma completed its IPO in June 2020, going public on the NASDAQ under the ticker symbol RPRX. The company raised approximately $2.2 billion in one of the largest biotech-related IPOs ever, pricing shares at $28 each. The IPO was significantly oversubscribed, reflecting strong investor demand for pharmaceutical royalty exposure. The company's public debut provided investors with a unique way to gain exposure to pharmaceutical innovation through royalty streams rather than direct drug development risk. Royalty Pharma used the IPO proceeds to fund additional royalty acquisitions and strengthen its position as the leading pharmaceutical royalty company. The successful IPO validated the royalty model as an attractive asset class for public market investors.
Frequently Asked Questions
Has Royalty Pharma had an IPO?
Yes, Royalty Pharma completed its IPO in June 2020. The pharmaceutical royalty company went public on the NASDAQ under the ticker symbol RPRX in one of the largest biotech-related IPOs ever.
When is the Royalty Pharma IPO date?
Royalty Pharma already had its IPO in June 2020. The company has been publicly traded since then on the NASDAQ.
How can I buy Royalty Pharma stock?
You can buy Royalty Pharma stock through any brokerage account using the ticker symbol RPRX. The stock trades on the NASDAQ and is available through most online brokers and investment platforms.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts